Skip to main content

Once-Weekly Insulin for Type 1 Diabetes

Published: 11/11/22 1:45 pm
By Andrew Briskin

A once-weekly insulin option would bring several benefits to people with type 1 diabetes. This study will evaluate the safety and glucose-lowering effect of an investigational once-weekly insulin compared with degludec.

Clinical Trials Identifier: NCT05463744

Trial Name: A Study of LY3209590 Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy (QWINT-5)

Diabetes Type: Adults with type 1 diabetes

Trial Sponsor: Eli LIlly & Co.

What is the trial testing?

This trial will investigate a once-weekly insulin called Basal Insulin Fc, or BIF (identified in the trial as LY3209590) in adults with type 1 diabetes. The study will evaluate BIF’s safety and will compare its glucose-lowering effect with insulin degludec, a popular once-daily insulin option commonly known by its brand name Tresiba. The trial will enroll 670 participants and measure changes in A1C over the course of 26 weeks. Researchers will also investigate BIF’s effects on time in range and time in hypoglycemia compared with degludec.

Why is this new trial important? 

There are currently no once-weekly insulin options available, however, there are several potential benefits to a once-weekly insulin option for people with type 1 diabetes. 

A once-weekly option means fewer injections for people with diabetes, which could improve the likelihood that people adhere to their medication regimen. Prior research on once-weekly medications has suggested that people with diabetes may be more likely to take their medications as scheduled with once-weekly injections compared with once-daily. Also, many people reported that taking an injection once daily was inconvenient. 

Trial Length: 52 weeks

Trial Locations: This is a multicenter, worldwide study with 87 locations across the United States, Puerto Rico, Argentina, India, Japan, Poland, Slovakia, and Taiwan. See a list of all participating locations here.

Are you interested?

You may be eligible to participate in this trial if:

  • You are 18 years or older and were diagnosed with type 1 diabetes at least one year before screening for the study

  • You have an A1C between 7.0% and 10.0%

  • You have NOT experienced more than one instance of severe hypoglycemia or DKA in the six months before screening for the study

See a full list of inclusion/exclusion criteria here

For more information: To learn more, contact the Eli Lilly study team at [email protected] or call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559.



What do you think?

About the authors

Drew Briskin joined the diaTribe Foundation in 2021 after graduating from the University of Pennsylvania where he majored in Health and Societies with a minor in Chemistry. As an undergraduate,... Read the full bio »